Data Insights

Risk adjusted net present value: What is the current valuation of I-Mab's Uliledlimab?

Uliledlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Oropharyngeal Cancer. According to Globaldata,...

Net Present Value Model: I-Mab's Uliledlimab

Data Insights

Uliledlimab by I-Mab for Ovarian Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Ovarian Cancer

Data Insights

Uliledlimab by I-Mab for Gastric Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Gastric Cancer

Data Insights

Uliledlimab by I-Mab for Fallopian Tube Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Fallopian Tube Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Fallopian Tube Cancer

Data Insights

Uliledlimab by I-Mab for Hypopharyngeal Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Hypopharyngeal Cancer

Data Insights

Uliledlimab by I-Mab for Laryngeal Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Laryngeal Cancer

Data Insights

Uliledlimab by I-Mab for Oropharyngeal Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Oropharyngeal Cancer

Data Insights

Uliledlimab by I-Mab for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Uliledlimab by I-Mab for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Oral Cavity (Mouth) Cancer

Data Insights

Uliledlimab by I-Mab for Peritoneal Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Peritoneal Cancer

Data Insights

Uliledlimab by I-Mab for Epithelial Ovarian Cancer: Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Epithelial Ovarian Cancer

Data Insights

Uliledlimab by I-Mab for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Triple-Negative Breast Cancer (TNBC)

Data Insights

Uliledlimab by I-Mab for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Uliledlimab is under clinical development by I-Mab and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....

Likelihood of Approval and Phase Transition Success Rate Model - Uliledlimab in Head And Neck Squamous Cell Carcinoma (HNSC)